DRUG · US market

BRIGHT MINDS BIOSCIENCES INC

Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.

Market cap US$481.63mFinancials dated 30 September 2024Price dated 1 October 2026

Core valuation

P/E · full-year fallback*-236.59×
Latest-quarter run-rate P/EUnavailable
Trailing P/SUnavailable
Latest-quarter run-rate P/SUnavailable

* P/E uses the latest reported full year ended 30 September 2024 because neither a trailing four-quarter value nor a latest-quarter value is available.

Calculation inputs

Trailing earnings
Unavailable
Latest-quarter run-rate earnings
Unavailable
Latest fiscal-year earnings
-US$2.04m
Trailing revenue
Unavailable
Latest-quarter run-rate revenue
Unavailable
Latest fiscal-year revenue
Unavailable

Featured ETF and mutual-fund exposure

These public funds report this company in their latest disclosed holdings.

Sources and limitations

Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.

Open financial source

Financials as of 30 September 2024. Informational research, not investment advice.